Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19449485 | 0.98 | SMN1; SMN2 (0.35) | SMN1; SMN2MEN1KMT2ATSHRHPGD | |
| SCHEMBL19449483 | 0.95 | SMN1; SMN2 (0.36) | SMN1; SMN2MEN1KMT2ATSHRHPGD | |
| SCHEMBL12448290 | 0.92 | — | — | |
| SCHEMBL12197833 | 0.84 | MEN1 (0.33) | SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL12243856 | 0.82 | MEN1 (0.40) | SMN1; SMN2MEN1KMT2ATSHRLMNA | |
| SCHEMBL17108539 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20374425 | 0.82 | GABRP (0.37) | SMN1; SMN2MEN1KMT2ATSHRPOLB | |
| SCHEMBL19248830 | 0.78 | LTA4H (0.42) | SMN1; SMN2HPGDLMNAPOLBRECQL | |
| SCHEMBL12243857 | 0.78 | SLC6A1 (0.46) | SMN1; SMN2MEN1KMT2ATSHRLMNA | |
| SCHEMBL23260712 | 0.76 | TSHR (0.40) | SMN1; SMN2MEN1KMT2ATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028938-B2 | Antiviral agents and uses thereof | GRIFFITH UNIVERSITY (AU) | 2018-07-24 | — | — | US | disclosed |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2017-10-12 | — | — | US | disclosed |
| US-9433626-B2 | Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434747-B2 | Methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9409910-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9271971-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9199996-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9085580-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184303-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130123277-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110237582-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2604/4885MEN1 3074/4885KMT2A 1323/4885 |
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2610/4885MEN1 3034/4885KMT2A 1364/4885 |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2610/4885MEN1 3034/4885KMT2A 1364/4885 |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2610/4885MEN1 3034/4885KMT2A 1364/4885 |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | SMN1; SMN2 3057/4885MEN1 1883/4885KMT2A 1190/4885 |
| US-20130123277-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | SMN1; SMN2 2648/4885MEN1 3198/4885KMT2A 1376/4885 |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | SMN1; SMN2 3057/4885MEN1 1883/4885KMT2A 1190/4885 |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | RNASE1, ENTPD5, ACE | SMN1; SMN2 3429/4885MEN1 3514/4885KMT2A 3066/4885 |
| US-10028938-B2 | Antiviral agents and uses thereof | RNASE1, ENTPD5, ACE | SMN1; SMN2 3429/4885MEN1 3514/4885KMT2A 3066/4885 |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | SMN1; SMN2 945/4885MEN1 4283/4885KMT2A 366/4885 |
| US-20130184303-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2610/4885MEN1 3034/4885KMT2A 1364/4885 |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 1391/4885MEN1 3937/4885KMT2A 2238/4885 |
| US-20110237582-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2604/4885MEN1 3074/4885KMT2A 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.